Rivastigmine patch for treatment of Alzheimer's disease in clinical practice in Thailand

• Published in: Psychogeriatrics Vol. 13; no. 1; pp. 1 - 8
• Main Authors: KULKANTRAKORN, Kongkiat, TANYAKITPISAL, Panas, TOWANABUT, Somchai, DEJTHEVAPORN, Charungthai, RANGSEEKAJEE, Poonsri, PONGPAKDEE, Sunsanee, LAPTIKULTHAM, Somsak, RODPRASERT, Kritsada, SETTHAWATCHARAWANICH, Suwanna, THINKHAMROP, Bandit
• Format: Journal Article
• Language: English
• Published: Melbourne, Australia Blackwell Publishing Asia 01.03.2013; Blackwell Publishing Ltd
• Subjects: Age; Aged; Alzheimer Disease - drug therapy; Alzheimer Disease - psychology; Alzheimer's disease; Cholinesterase Inhibitors - administration & dosage; Cholinesterase Inhibitors - adverse effects; Cognition - drug effects; cognitive functioning; Dose-Response Relationship, Drug; Drug therapy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Phenylcarbamates - administration & dosage; Phenylcarbamates - adverse effects; Prospective Studies; Rivastigmine; safety; Severity of Illness Index; Thailand; tolerability; Transdermal medication; Transdermal Patch; Treatment Outcome; Thailand

Background:  Rivastigmine is a cholinesterase inhibitor for treatment of mild to moderate Alzheimer's disease (AD) and dementia associated with Parkinson's disease. The new patch formulation was recently made available. We assessed the safety, tolerability, and cognitive outcome of rivasti...